Gene Sets Altered Across Brain Regions in Schizophrenia, Bipolar Disorder & MDD
Until now, the majority of postmortem research that has examined functionally related gene sets has been limited to a single disorder or region of the brain.
Neuropsychiatric
Bipolar and Schizophrenia Disorders Accurately Predicted With WERCAP Sections
By using the Washington Early Recognition Center Affectivity and Psychosis (WERCAP) questionnaire, investigators accurately predicted bipolar disorder or schizophrenia in more than 85% of patients.
Pupillometric Analysis For Assessment of Depression Recurrence
Pupillary reactivity to emotional stimuli has been investigated to provide objective information about the risk for recurrence of depressive symptoms in women.
White Matter Abnormalities and Clinical Symptom Severity in Schizophrenia
New findings provide an insight about the association between white matter microstructure and the severity of schizophrenia clinical symptoms.
Interaction of Proline and COMT Genotype Influences Negative Symptoms in Schizophrenia & Bipolar Disorder
The authors explored whether valproate (VPA) treatment effects vary by catechol-O-methyltransferase (COMT) genotype.
Whole Body Hyperthermia: The Future of Depression Treatment?
Researchers investigated the lasting effects of whole body hyperthermia (WBH) in the first randomized, double-blind, [placebo]-controlled study of WBH for the treatment of MDD.
mPFC Abnormalities Associated With Social Cognition Deficits in Schizophrenia
Poor psychosocial functioning among individuals diagnosed with schizophrenia is associated with deficits in social cognition.
Neuroinflammation in Schizophrenia: New PET Brain Imaging Studies
TSPO expression is frequently used as a biomarker for brain inflammation during PET imaging.
Clinical, But Not Subclinical, Psychosis Linked with Less Physical Activity
Low physical activity was defined as less than 150 minutes of moderate-to-vigorous exercise per week.
A Potential Biomarker for the Onset of Psychosis in High-risk Individuals
Researchers used the auditory mismatch negativity (MMN) paradigm to evaluate its potential as a neurophysiological biomarker for psychosis.
-
Loading...
-
Loading...
Next post in Schizophrenia and Psychoses
